ArticleDiagnostic pathology2010
Tissue microarrays: one size does not fit all.
Article in Diagnostic pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.PloS one · 2014Pooled it
- Expression of LAG-3, TIM-3, and VISTA on Tumor-Infiltrating Lymphocytes in Advanced Laryngeal Squamous Cell Carcinoma and Their Association with CD8+ TIL Density.Biomedicines · 2026Article
- Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.Scientific reports · 2023Article
- Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma.Biological trace element research · 2023Article
- Optimizing multiplexed imaging experimental design through tissue spatial segregation estimation.Nature methods · 2023Article
- Preparation, construction and high-throughput automated analysis of human brain tissue microarrays for neurodegenerative disease drug development.Nature protocols · 2021Article
- Review
- Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.International journal of clinical and experimental pathology · 2021Article
- Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.European urology focus · 2019Review
- Article
- Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer.Oncotarget · 2018Article
- Sampling strategies to capture single-cell heterogeneity.Nature methods · 2017Article
- Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score.Scientific reports · 2016Article
- PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.Cancer immunology research · 2015Article
- SpOT the Correct Tissue Every Time in Multi-tissue Blocks.Journal of visualized experiments : JoVE · 2015Article
- PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?Journal of clinical pathology · 2015Article
- Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.Urologic oncology · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAlthough tissue microarrays (TMAs) are commonly employed in clinical and basic-science research, there are no guidelines for evaluating the appropriateness of a TMA for a given biomarker and tumor type. Furthermore, TMA performance across multiple biomarkers has not been systematically explored.
methodsA simulated TMA with between 1 and 10 cores was designed to study tumor expression of 6 biomarkers with varied expression patterns (B7-H1, B7-H3, survivin, Ki-67, CAIX, and IMP3) using 100 patients with clear cell renal cell carcinoma (RCC). We evaluated agreement between whole tissue section and TMA immunohistochemical biomarker quantification to assess how many TMA cores are necessary to adequately represent RCC whole tissue section expression. Additionally, we evaluated associations of whole tissue section and TMA expression with RCC-specific death.
resultsThe number of simulated TMA cores necessary to adequately represent whole tissue section quantification is biomarker specific. Although 2-3 cores appeared adequate for B7-H3, Ki-67, CAIX, and IMP3, even as many as 10 cores resulted in poor agreement for B7-H1 and survivin compared to RCC whole tissue sections. While whole tissue section B7-H1 was significantly associated with RCC-specific death, no significant associations were detected using as many as 10 TMA cores, suggesting that TMAs can result in false-negative findings if the TMA is not optimally designed.
conclusionsPrior to TMA analysis, the number of TMA cores necessary to accurately represent biomarker expression on whole tissue sections should be established as there is not a one-size-fits-all TMA. We illustrate the use of a simulated TMA as a cost-effective tool for this purpose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.